Sb Technology Holdings, Inc. (BIOM) Stock Price & Analysis

Sb Technology Holdings, Inc. (BIOM) rose 1035.80% to USD 0.46 as of July 25, 2026 at 06:09 UTC, according to Nexqual real-time market data.

BIOM last closed at USD 0.04; the session ranged USD 0.34–0.34 on volume of 1 shares. Market capitalization is $485,196, with a 52-week range of USD 0.03–2.25 (OID). Source: Nexqual, July 25, 2026 at 06:09 UTC.

Key Statistics (as of July 25, 2026 at 06:09 UTC)

Technical Analysis (BIOM)

Nexqual's technical model rates BIOM "NEUTRAL" based on 3 bullish and 2 bearish signals across 124 daily candles, as of July 25, 2026 at 06:09 UTC.

Analyst Ratings (BIOM)

Wall Street analysts rate BIOM "None", per Nexqual as of July 25, 2026 at 06:09 UTC.

Earnings (BIOM)

Recent Earnings History

Source: Nexqual, July 25, 2026 at 06:09 UTC.

Financials & Fundamentals (BIOM)

Source: Nexqual, July 25, 2026 at 06:09 UTC.

Financial Health Score (BIOM)

Nexqual rates Sb Technology Holdings, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:09 UTC.

Ownership (BIOM)

Source: Nexqual, July 25, 2026 at 06:09 UTC.

Leadership (BIOM)

Sb Technology Holdings, Inc. is led by William P. Farrand (age 61), President, CEO & Director, per Nexqual as of July 25, 2026 at 06:09 UTC.

From Sb Technology Holdings, Inc.'s Latest SEC 10-K Filing (filed 2015-04-15)

Key Strengths & Strategy (as disclosed to the SEC)

• As there are over 200 million possible combinations of approved and development-stage oncological drugs, not including the hundreds of MDT oncological agents patented (Nature Biotechnology, Vol. 30 No 7 July 2012), it is more relevant to discuss the competition that may be faced by the sorafenib/hydroxychloroquine, or HCQ, treatment in an FDA phase I study.
• Patent Applications we own or co-own _______________ The rights we consider significant in relation to our business as a whole are covered by two exclusive license agreements we entered into with the University of Colorado, one of which pertains to patents and patent applications concerning TPT, referred to as the CLIP License, and the other concerning MDT, referred to as the Metabolic Distribution License.
• We take measures to protect our proprietary know-how, technologies, and confidential data, including requiring all employees, consultants and customers to enter into confidentiality agreements.
• Rogers and the universities for whom she has worked, we have collaborated with: History of Our Technology Prior to our acquisition of Viral Genetics in 2001, Viral Genetics had acquired the right to use certain technology, called Thymus Nuclear Protein, or TNP, through license agreements.

Partnerships

• Clip License On August 25, 2009, we entered into a worldwide exclusive license agreement with the University of Colorado granting us rights to patents, patent applications, and technologies developed by Dr.
• Metabolic Distribution License On November 22, 2009, we entered into a worldwide exclusive license agreement with the University of Colorado granting us rights to patents, patent applications, and technologies developed by Dr.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:09 UTC. This page is informational and not investment advice.